Daxor Corporation (DXR)vsMedline Inc. Class A Common Stock (MDLN)
DXR
Daxor Corporation
$10.23
-2.66%
HEALTHCARE · Cap: $63.75M
MDLN
Medline Inc. Class A Common Stock
$42.67
+1.52%
HEALTHCARE · Cap: $34.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 106526685% more annual revenue ($28.43B vs $26,690). DXR leads profitability with a 343.6% profit margin vs 4.1%. DXR trades at a lower P/E of 6.7x. MDLN earns a higher WallStSmart Score of 52/100 (C-).
DXR
Hold45
out of 100
Grade: D+
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.6%
Fair Value
$76.75
Current Price
$10.23
$66.52 discount
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.67
$24.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 344 of every $100 in revenue as profit
Every $100 of equity generates 23 in profit
No standout strengths identified
Areas to Watch
3.3% earnings growth
Smaller company, higher risk/reward
Revenue declined 82.6%
Negative free cash flow — burning cash
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 343.6% and operating margin at -96.6%.
Bull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bear Case : DXR
The primary concerns for DXR are EPS Growth, Market Cap, Revenue Growth.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
DXR profiles as a declining stock while MDLN is a value play — different risk/reward profiles.
MDLN is growing revenue faster at 14.8% — sustainability is the question.
DXR generates stronger free cash flow (-297,470), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 45/100) and 14.8% revenue growth. DXR offers better value entry with a 83.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?